Flagship Pioneering Innovations VI LLC has disclosed ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), Parkinson’s disease and cancer.